FDA.reportPublic FDA data

40 ML immunoglobulin G, human 200 MG/ML Injection

RxCUI
1813423
RxNorm name
40 ML immunoglobulin G, human 200 MG/ML Injection
Display name
40 ML immunoglobulin G, human 200 MG/ML Injection
Full name
40 ML immunoglobulin G, human 200 MG/ML Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:10

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125596CuvitruImmune Globulin Subcutaneous (Human), 20% Solution351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
9aad7ec9-6097-4805-8f1b-898bec35f21840 ML immunoglobulin G, human 200 MG/ML InjectionSCD19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f218immunoglobulin G, human 8 GM per 40 ML InjectionSY19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f218immunoglobulin G, human 20 % in 40 mL InjectionPSN19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125
9aad7ec9-6097-4805-8f1b-898bec35f218immunoglobulin G, human 20 % per 40 ML InjectionSY19These highlights do not include all the information needed to use CUVITRU ® safely and effectively. See full prescribing information for CUVITRU. CUVITRU ® , Immune Globulin Subcutaneous (Human), 20% Solution Initial U.S. Approval: 201620251125